These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 6262895)

  • 1. [Molecular action of drugs affecting platelet functions (author's transl)].
    Verstraete M
    Rev Med Brux; 1981 Mar; 2(3):301-8. PubMed ID: 6262895
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacology of platelet-affecting drugs.
    Packham MA; Mustard JF
    Circulation; 1980 Dec; 62(6 Pt 2):V26-41. PubMed ID: 6254690
    [No Abstract]   [Full Text] [Related]  

  • 3. [Mechanism of action of antiplatelet medication].
    Navarro JL; Frade FJ; Alava I; Obispo T; Trejo R; Jiménez C; Cesar J
    Sangre (Barc); 1984; 29(4-C):817-32. PubMed ID: 6096974
    [No Abstract]   [Full Text] [Related]  

  • 4. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.
    Aiken JW; Shebuski RJ; Miller OV; Gorman RR
    J Pharmacol Exp Ther; 1981 Nov; 219(2):299-308. PubMed ID: 6270303
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pharmacologic and dietary management of prostaglandin synthesis in the prevention of thrombosis].
    Carreras LO
    Sangre (Barc); 1982; 27(2):198-217. PubMed ID: 6289481
    [No Abstract]   [Full Text] [Related]  

  • 6. A pharmacological approach to the inhibition of platelet adhesion and platelet aggregation. Wright-Schulte Lecture.
    Verstraete M
    Haemostasis; 1982; 12(4):317-36. PubMed ID: 6295896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Status and trends in the field of inhibitors of thrombocyte function].
    Glusa E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(4):575-9. PubMed ID: 6083929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Enzyme inhibitors and receptor antagonists in the arachidonic cascade].
    Arai Y; Kawamura M
    Nihon Rinsho; 1990 Jun; 48(6):1120-8. PubMed ID: 2166837
    [No Abstract]   [Full Text] [Related]  

  • 9. The biological role of thromboxane A2 in the process of hemostasis and thrombosis; pharmacology and perspectives of therapeutical use of thromboxane synthetase inhibitors and receptor PGH2/TXA2 antagonists.
    Radomski M
    Acta Physiol Pol; 1985; 36(3):153-64. PubMed ID: 3915630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostacyclin and arterial wall biology.
    Moncada S
    Arteriosclerosis; 1982; 2(3):193-207. PubMed ID: 6284099
    [No Abstract]   [Full Text] [Related]  

  • 11. [Studies on platelet aggregation inhibitory agents (author's transl)].
    Ukita M; Kitahara T; Hosokawa T; Kato M; Suzuki Y; Otomo H
    Nihon Ketsueki Gakkai Zasshi; 1974 Apr; 37(2):161-5. PubMed ID: 4369675
    [No Abstract]   [Full Text] [Related]  

  • 12. [Inhibition of platelet aggregation and its clinical use (author's transl)].
    Cepelák V
    Cas Lek Cesk; 1974 Jan; 113(2):51-5. PubMed ID: 4154807
    [No Abstract]   [Full Text] [Related]  

  • 13. [Comparative study of the inhibitory effect on platelet aggregation of various anti-inflammatory drugs].
    Migne J; Santonja R; Kunz S
    Therapie; 1973; 28(5):861-76. PubMed ID: 4368089
    [No Abstract]   [Full Text] [Related]  

  • 14. An overview of antiplatelet and antithrombotic drugs.
    Verstraete M; Dejana E; Fuster V; Lapetina E; Moncada S; Mustard JF; Tans G; Vargaftig BB
    Haemostasis; 1985; 15(2):89-99. PubMed ID: 3159632
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pharmacology of anti-platelet agents].
    Lecompte T; Kher A; Gaillard JL; Samama M
    J Mal Vasc; 1983; 8(1):3-16. PubMed ID: 6302191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of prostacycline, thromboxane A2 and prostaglandins in platelet aggregation (author's transl)].
    Herman AG
    Rev Med Brux; 1981 Mar; 2(3):251-7. PubMed ID: 7015444
    [No Abstract]   [Full Text] [Related]  

  • 17. Differential effects of cyclo-oxygenase inhibitors and thromboxane synthase inhibitors on rabbit platelet aggregation: evidence for the importance of prostaglandin endoperoxides as mediators in arachidonate-induced aggregation but not in collagen-induced aggregation.
    Wallis RB; Zelaschi D
    Biochem Soc Trans; 1980 Dec; 8(6):726-7. PubMed ID: 6780392
    [No Abstract]   [Full Text] [Related]  

  • 18. [Hyperaggregability of platelet in acute stage of thrombosis (author's transl)].
    Yamazaki H; Takahashi T; Mashimo N
    Rinsho Ketsueki; 1973 Dec; 14(0):1365-71. PubMed ID: 4807611
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacology of platelet-suppressive agents.
    Wautier JL; Caen JP
    Semin Thromb Hemost; 1979; 5(4):293-315. PubMed ID: 386519
    [No Abstract]   [Full Text] [Related]  

  • 20. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
    Hoet B; Arnout J; Deckmyn H; Vermylen J
    Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.